Mindbloom

About Mindbloom

Mindbloom is the leading consumer psychedelic therapy brand and the first and largest national provider of ketamine therapy for depression, anxiety, and PTSD. Founded in 2018, the company delivers clinically effective treatment with a premium client experience at an affordable price, entirely from home. With over 800,000 sessions delivered across 38 states, Mindbloom has established itself as the #1 trusted brand in psychedelic therapy. The company is expanding its pipeline to include next-generation psychedelic medicines such as MDMA and psilocybin, backed by Tier 1 investors including Kleiner Perkins, 8VC, and Founders Fund.